









- matol Oncol Clin North Am*, 32(5):865-874.  
<https://doi.org/10.1016/j.hoc.2018.05.013>
- Locke FL, Ghobadi A, Jacobson CA, et al., 2019. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol*, 20(1):31-42.  
[https://doi.org/10.1016/S1470-2045\(18\)30864-7](https://doi.org/10.1016/S1470-2045(18)30864-7)
- Owen RG, Treon SP, Al-Katib A, et al., 2003. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Semin Oncol*, 30(2):110-115.  
<https://doi.org/10.1053/sonc.2003.50082>
- Palomba ML, Qualls D, Monette S, et al., 2022. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. *J Immunother Cancer*, 10(2).  
<https://doi.org/10.1136/jitc-2021-004128>
- Ruan G, Zanwar S, Abeykoon JP, et al., 2020. Predictors of short-term survival in Waldenström Macroglobulinemia. *Leuk Lymphoma*, 61(12):2975-2979.  
<https://doi.org/10.1080/10428194.2020.1789625>
- Shadman M, 2022. Shadman M. CD20 CAR-T therapy for WM and other B-NHLs. Presented at: IWWM-11, October 29, 2022, Madrid, Spain .
- Thompson PA, Tam CS, 2023. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. *Blood*, 141(26):3137-3142.  
<https://doi.org/10.1182/blood.2023020240>
- Treon SP, 2015. How I treat Waldenström macroglobulinemia. *Blood*, 126(6):721-732.  
<https://doi.org/10.1182/blood-2015-01-553974>
- Treon SP, Tedeschi A, San-Miguel J, et al., 2023. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. *Semin Hematol*, 60(2):97-106.  
<https://doi.org/10.1053/j.seminhematol.2023.03.009>

unedited